Source: http://www.law.cornell.edu/uscode/text/21/356b?quicktabs_8=4
Timestamp: 2014-09-01 23:44:58
Document Index: 274233850

Matched Legal Cases: ['§ 356', '§ 506', '§ 130', '§ 506', '§ 902', '§ 508', '§ 501', '§ 130', '§ 356', 'art 5', 'art 7', 'art 10', 'art 11', 'art 12', 'art 13', 'art 14', 'art 15', 'art 16', 'art 20', 'art 25', 'art 314', 'art 570', 'art 571', 'art 700']

21 U.S. Code § 356b - Reports of postmarketing studies | LII / Legal Information Institute
In general A sponsor of a drug that has entered into an agreement with the Secretary to conduct a postmarketing study of a drug shall submit to the Secretary, within 1 year after the approval of such drug and annually thereafter until the study is completed or terminated, a report of the progress of the study or the reasons for the failure of the sponsor to conduct the study. The report shall be submitted in such form as is prescribed by the Secretary in regulations issued by the Secretary.
Agreements prior to effective date Any agreement entered into between the Secretary and a sponsor of a drug, prior to November 21, 1997, to conduct a postmarketing study of a drug shall be subject to the requirements of paragraph (1). An initial report for such an agreement shall be submitted within 6 months after the date of the issuance of the regulations under paragraph (1).
Consideration of information as public information Any information pertaining to a report described in subsection (a) of this section shall be considered to be public information to the extent that the information is necessary—
to establish the status of a study described in subsection (a) of this section and the reasons, if any, for any failure to carry out the study.
Status of studies and reports The Secretary shall annually develop and publish in the Federal Register a report that provides information on the status of the postmarketing studies—
for which reports have been submitted under subsection (a)(1) of this section.
Disclosure If a sponsor fails to complete an agreed upon study required by this section by its original or otherwise negotiated deadline, the Secretary shall publish a statement on the Internet site of the Food and Drug Administration stating that the study was not completed and, if the reasons for such failure to complete the study were not satisfactory to the Secretary, a statement that such reasons were not satisfactory to the Secretary.
Notification With respect to studies of the type required under section 356
(c)(2)(A) of this title or under section 314.510 or 601.41 of title 21, Code of Federal Regulations, as each of such sections was in effect on the day before the effective date of this subsection, the Secretary may require that a sponsor who, for reasons not satisfactory to the Secretary, fails to complete by its deadline a study under any of such sections of such type for a drug or biological product (including such a study conducted after such effective date) notify practitioners who prescribe such drug or biological product of the failure to complete such study and the questions of clinical benefit, and, where appropriate, questions of safety, that remain unanswered as a result of the failure to complete such study. Nothing in this subsection shall be construed as altering the requirements of the types of studies required under section 356
(c)(2)(A) of this title or under section 314.510 or 601.41 of title 21, Code of Federal Regulations, as so in effect, or as prohibiting the Secretary from modifying such sections of title 21 of such Code to provide for studies in addition to those of such type.
(June 25, 1938, ch. 675, § 506B, as added Pub. L. 105–115, title I, § 130(a),Nov. 21, 1997, 111 Stat. 2331; amended Pub. L. 107–188, title V, § 506,June 12, 2002, 116 Stat. 693; Pub. L. 112–144, title IX, § 902(c),July 9, 2012, 126 Stat. 1088.)
2012—Subsec. (e). Pub. L. 112–144substituted “section 356
(c)(2)(A) of this title” for “section 356
(b)(2)(A) of this title” in two places.
2002—Subsecs. (d), (e). Pub. L. 107–188added subsecs. (d) and (e).
Pub. L. 107–188, title V, § 508,June 12, 2002, 116 Stat. 694, provided that: “The amendments made by this subtitle [subtitle A (§§ 501–509) of title V of Pub. L. 107–188, amending this section and sections 379g and 379h of this title] shall take effect October 1, 2002.”
Pub. L. 105–115, title I, § 130(b),Nov. 21, 1997, 111 Stat. 2331, provided that not later than Oct. 1, 2001, the Secretary was to submit to Congress a report containing a summary of the reports submitted under section 356b of this title and an evaluation and legislative recommendations relating to postmarketing studies of drugs.
21 USCDescription of ChangeSession YearPublic LawStatutes at Large § 356b2012112-144 [Sec.] 902(c)126 Stat. 1088 This is a list of parts within the Code of Federal Regulations for which this US Code section provides rulemaking authority.This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.21 CFR - Food and Drugs21 CFR Part 5 - ORGANIZATION21 CFR Part 7 - ENFORCEMENT POLICY21 CFR Part 10 - ADMINISTRATIVE PRACTICES AND PROCEDURES21 CFR Part 11 - ELECTRONIC RECORDS; ELECTRONIC SIGNATURES21 CFR Part 12 - FORMAL EVIDENTIARY PUBLIC HEARING21 CFR Part 13 - PUBLIC HEARING BEFORE A PUBLIC BOARD OF INQUIRY21 CFR Part 14 - PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE21 CFR Part 15 - PUBLIC HEARING BEFORE THE COMMISSIONER21 CFR Part 16 - REGULATORY HEARING BEFORE THE FOOD AND DRUG ADMINISTRATION21 CFR Part 20 - PUBLIC INFORMATION21 CFR Part 25 - ENVIRONMENTAL IMPACT CONSIDERATIONS21 CFR Part 314 - APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG21 CFR Part 570 - FOOD ADDITIVES21 CFR Part 571 - FOOD ADDITIVE PETITIONS21 CFR Part 700 - GENERAL